DexCom, Inc. reported significant financial growth in its latest quarterly results, with revenue reaching $1.19 billion for the three months ended March 31, 2026, a 15% increase from $1.04 billion in the same period last year. The company's gross profit also saw a substantial rise, climbing to $750.3 million, up 27% from $589 million in the prior year. Operating income surged by 91% to $255.3 million, while net income nearly doubled, increasing 89% to $199.5 million. This translates to a basic net income per share of $0.52, compared to $0.27 in the previous year.
The financial performance reflects a strong demand for DexCom's continuous glucose monitoring (CGM) systems, particularly its disposable sensors. The company added approximately 600,000 to 700,000 net customers in 2025, excluding those using its Stelo product, which contributed to the revenue growth. However, the increase was somewhat tempered by pricing pressures related to channel mix and rebate eligibility. Cost of sales decreased slightly, attributed to improved manufacturing efficiencies and a favorable production mix, which enhanced gross margins.
In terms of operational developments, DexCom launched its latest generation CGM systems, including the Dexcom G7 and the Dexcom G7 15 Day Continuous Glucose Monitoring System, in 2023 and late 2025, respectively. The company also introduced Stelo, a biosensor for adults with prediabetes and Type 2 diabetes, marking its entry into the over-the-counter glucose monitoring market. These product launches are part of DexCom's strategy to expand its offerings and enhance its market position.
Geographically, the majority of DexCom's revenue continues to be generated in the United States, with international sales also contributing significantly. The company reported total revenue of $832.3 million from the U.S. and $359.6 million from international markets in the latest quarter. The company maintains a strong liquidity position, with cash, cash equivalents, and short-term marketable securities totaling $2.42 billion as of March 31, 2026, an increase from $2.00 billion at the end of 2025.
Looking ahead, DexCom plans to continue investing in research and development to enhance its product offerings and expand its market reach. The company aims to develop future generations of technologies focused on improved performance and convenience, as well as explore opportunities in other health-related areas. With a solid financial foundation and a growing customer base, DexCom is well-positioned to capitalize on the increasing demand for diabetes management solutions.
About DEXCOM INC
DexCom, Inc. designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes management. Its core products include the Dexcom G6, G7, and Dexcom ONE systems, providing real-time glucose data to patients, caregivers, and healthcare providers. The company focuses on innovation, integration with insulin delivery devices, and expanding access through partnerships, aiming to improve health outcomes and reduce diabetes-related complications worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.